Clara Biotech Revenue and Competitors

Clara Diagnostics is developing the Exosome Sorting System (ExoSS), a high-throughput microfluidic system for the isolation and purification of exosomes. The company aims to launch the first microfluidic exosome sorting device (ExoSS) into the marketplace for automated, high-specificity, and high throughput preparation of exact exosome subtypes from a variety of biofluids. The ExoSS system performs isolation 100x faster than ultracentrifugation and able to extract greater than 90% of exosomes with an isolation purity greater than 90%. ExoSS rapidly runs parallel samples continuously, resulting in a platform ideal for large volume processing. Designed for low skill automation, ExoSS has the advantage of extracting all or only specific types of exosomes from the biological source. An On Site Non-Clinical Isolation Service (ExoSS OnSite) was launched in November 2018 by the company utilizing the existing ExoSS system. Clara Diagnostics is focused on establishing strategic partnerships for development in diagnostic and therapeutic applications, equipment manufacturing, antibody sourcing, distribution, sales and marketing.